VYLOY® with CAPOX - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin) and XELODA® (Capecitabine). Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positive
12
N/A
The first dose is given at 800 mg/m2 and subsequent doses are given at 600 mg/m2 every 3 weeks or 400 mg/m2 every 2 weeks. Monitor for hypersensitivity reactions, severe nausea and/or vomiting
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
VYLOY® (Zolbetuximab) IV 800 mg/m2 D1 N/A NSS 1000 cc 4-5 hours
VYLOY® (Zolbetuximab) IV 600 mg/m2 D1 q21 NSS 500 cc 3-4 hours
ELOXATIN® (Oxaliplatin) IV 130 mg/m2 D1 q21 D5W 250 cc 120 minutes
XELODA® (Capecitabine) PO 1000 mg/m2 D1-14 q21 N/A N/A N/A